CHICAGO — A massive, real-world analysis presented at ENDO 2026, the annual meeting of the Endocrine Society, has shed new light on the complex relationship between cornerstone diabetes medications and limb health. The study suggests that for adults with type 2 diabetes, the choice between GLP-1 receptor agonists and SGLT2 inhibitors may carry significantly different implications for the risk of major diabetic foot complications.
The findings, presented by Christie Polycarpe, DO, of Jefferson Einstein Philadelphia Hospital in Pennsylvania, highlight a critical clinical nuance: while both drug classes are heralded for their life-saving cardiovascular and renal benefits, their impact on the lower extremities—a frequent site of debilitating morbidity in diabetic patients—varies in ways that clinicians must now carefully consider.
The Core Findings: A Tale of Two Therapies
The retrospective analysis, which utilized the vast TriNetX database, compared outcomes in over 1.2 million patients with type 2 diabetes. After rigorous propensity score matching to account for demographics, baseline comorbidities—such as peripheral artery disease, cardiovascular disease, and chronic kidney disease—and concurrent medications, researchers identified a distinct divergence in outcomes.
The data indicated that patients treated with GLP-1 receptor agonists experienced significantly lower risks of major diabetic foot complications over a five-year follow-up period compared to those treated with SGLT2 inhibitors. While SGLT2 inhibitors have been celebrated for their ability to reduce hospitalizations for heart failure and slow the progression of chronic kidney disease, this analysis suggests they may come with a higher "foot-related tax" compared to their GLP-1 counterparts.
Interestingly, the study revealed a paradox: SGLT2 inhibitors were associated with a very small but statistically significant reduction in the risk of new-onset diabetic peripheral neuropathy (Relative Risk 0.97; 95% CI 0.93–0.98; P<0.001). However, as Polycarpe emphasized, this reduction in neuropathy did not translate into a lower incidence of actual foot events, such as ulcers, infections, or amputations.
Chronology of a Clinical Controversy: From CANVAS to Modern Practice
To understand the weight of these findings, one must view them through the historical lens of diabetes pharmacology. The relationship between SGLT2 inhibitors and limb health has been a subject of intense scrutiny for over a decade.
The CANVAS Signal
The conversation began in earnest with the CANVAS (CANagliflozin cardioVascular Assessment Study) clinical program. As the first SGLT2 inhibitor to reach the U.S. market in 2013, canagliflozin was initially greeted with optimism. However, clinical data later suggested an unexpected safety signal: an increased risk of leg and foot amputations in patients taking the drug.
The Regulatory Response
In response to the CANVAS data, the FDA mandated a boxed warning—the most stringent warning issued by the agency—on the label for canagliflozin, cautioning physicians and patients about the potential for lower-limb amputations.
The Reversal
The medical community remained divided as subsequent trials failed to replicate the amputation signal consistently. As more robust, long-term cardiovascular and kidney outcome trials (CVOTs) demonstrated that the benefits of SGLT2 inhibitors in reducing mortality and heart failure significantly outweighed the adjusted risks of limb events, the FDA ultimately removed the boxed warning in 2020. Despite this, the lingering question of "amputation risk" has continued to influence both clinical practice and class-level meta-analyses.
The Emergence of GLP-1 Evidence
Conversely, GLP-1 receptor agonists have generally avoided this controversy. Recent data, including a retrospective study from Taiwan published in early 2026, reinforced the protective profile of GLP-1 drugs. That study found that new users of GLP-1 agonists had a 10% lower risk of recurring major adverse limb events—defined as chronic limb-threatening ischemia, lower limb revascularization, or nontraumatic amputation—compared to those on DPP-4 inhibitors.
Supporting Data and Methodology
The study presented by Dr. Polycarpe is one of the largest of its kind, involving 630,097 patients in each of the two treatment arms. The strength of the study lies in its scale and the use of propensity matching to create a "level playing field" between the two groups.
By excluding patients who were receiving both classes of medication simultaneously, the researchers were able to isolate the independent associations of GLP-1 and SGLT2 therapy.
The Multifactorial Nature of Diabetic Foot Disease
Polycarpe’s assertion that "lower neuropathy risk did not mean fewer foot events" is perhaps the most vital takeaway for endocrinologists and podiatrists. Diabetic foot disease is notoriously complex, involving a confluence of:
- Macrovascular disease: Atherosclerosis affecting the arteries of the legs.
- Microvascular disease: Damage to the small blood vessels and nerves.
- Biomechanical factors: Pressure points, gait changes, and poor wound healing capacity.
The researchers acknowledged in their abstract that "neuropathy risk alone may not fully account for downstream foot complications." This suggests that the mechanism by which SGLT2 inhibitors might influence limb outcomes is not merely about nerve health, but potentially involves systemic hemodynamic changes, fluid shifts, or other factors that impact peripheral perfusion.
Clinical Implications: The Need for Individualization
The findings presented at ENDO 2026 do not suggest that SGLT2 inhibitors should be abandoned. On the contrary, their cardiorenal protection remains an essential component of modern diabetes care. Instead, the study serves as a call for "individualized therapy."
A New Paradigm for Foot Surveillance
For patients with a high risk of diabetic foot complications—such as those with a history of prior ulcers, severe peripheral artery disease, or long-standing, poorly controlled diabetes—the choice of therapy should be nuanced.
Dr. Polycarpe suggests that if a patient is at high risk for foot-related issues, the clinician must prioritize:
- Enhanced Foot Surveillance: Regular, formal podiatric exams.
- Multidisciplinary Care: Coordination between the endocrinologist, vascular surgeon, and podiatrist.
- Therapeutic Selection: Considering GLP-1 agonists as a primary option if the patient’s foot-risk profile is high, while reserving SGLT2 inhibitors for patients where cardiorenal protection is the overriding clinical priority.
Expert Perspectives and Future Directions
The limitations of the study, as noted by the research team, are inherent to the observational nature of the TriNetX database. Retrospective analyses can be subject to "confounding by indication"—where the physician’s choice of drug is influenced by the patient’s underlying health status in ways that the propensity score matching may not fully capture.
"Prospective studies and agent-specific comparative analyses are needed to further clarify differential risks and guide individualized therapeutic decision-making," the researchers stated in their report.
As the medical community moves forward, several key questions remain:
- Are these effects consistent across all GLP-1 and SGLT2 agents? For instance, does semaglutide differ from liraglutide in limb outcomes? Does empagliflozin show a different profile than canagliflozin?
- What is the underlying biological mechanism? If SGLT2 inhibitors indeed increase limb risk, is it due to hemoconcentration, changes in distal blood flow, or something yet to be discovered?
Conclusion
The data presented at ENDO 2026 marks a significant step forward in our understanding of how life-saving diabetes medications interact with the limbs of our most vulnerable patients. While the cardiorenal benefits of SGLT2 inhibitors remain indisputable, the signal suggesting a higher risk of diabetic foot complications compared to GLP-1 receptor agonists cannot be ignored.
Ultimately, the goal for the clinician is to move away from a "one-size-fits-all" approach. As Dr. Polycarpe concluded, the future of diabetes care lies in the synthesis of large-scale, real-world data with individualized patient assessments. By placing a renewed emphasis on foot surveillance and making informed choices about therapeutic classes, clinicians can better balance the systemic benefits of these powerful drugs against the local risks they may pose to the lower extremities. As more prospective data emerge, the medical community will be better equipped to provide care that protects not only the heart and kidneys but also the patient’s mobility.
